|
|
Volumn 11, Issue 11, 2012, Pages 822-
|
|
Deal watch: J&J and Genmab deal to push forward CD38 as a blood cancer target
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BORTEZOMIB;
CARFILZOMIB;
CD38 ANTIGEN;
DARATUMUMAB;
LENALIDOMIDE;
MONOCLONAL ANTIBODY;
MOR 03087;
RITUXIMAB;
SAR 650984;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
B CELL LYMPHOMA;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
COMPLEMENT SYSTEM;
DRUG CYTOTOXICITY;
DRUG DESIGN;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TARGETING;
HUMAN;
MAINTENANCE CHEMOTHERAPY;
MULTIPLE MYELOMA;
MYELOMA CELL;
NOTE;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
UNSPECIFIED SIDE EFFECT;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD38;
ANTINEOPLASTIC AGENTS;
COOPERATIVE BEHAVIOR;
DRUG DESIGN;
DRUG INDUSTRY;
HEMATOLOGIC NEOPLASMS;
HUMANS;
|
|
EID: 84868366992
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3890 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|
